Biomax Informatics Collaborates with Pierre Fabre
News Jun 25, 2015
Biomax Informatics AG and Pierre Fabre have announced a collaboration to create an integrated antibody sequence and knowledge database. Following a successful pilot project, Pierre Fabre has licensed Biomax’s BioXM™ Knowledge Management Environment and agreed on a continuous refinement and expansion of the system for comprehensive support of their antibody development process.
Biomax used their BioXM™ Knowledge Management Environment to configure a centralized antibody sequence and knowledge base that supports Pierre Fabre’s antibody discovery process. The knowledge base comprises sophisticated sequence analysis and storage, a platform to share in-house data and algorithms, public data, and both public and third-party algorithms. Pierre Fabre researchers have quickly adopted the platform to collect and generate further knowledge.
“We have improved our database quality by a centralized bioinformatics system tailored to our needs in analyzing and validating our antibody discovery data,” said Dr. M. Tesar, Head of the Molecular and Cellular Department at Pierre Fabre Immunology Center. “We were impressed how quickly Biomax took our experts’ concepts and turned them into a software solution that efficiently supports our daily work. The improvement to our antibody R&D process has been invaluable.”
“This project represents exactly what Biomax strives to do: give researchers the tools that help them leverage their big concepts, capture knowledge and add value to their research,” said Dr. Philipp Krubasik, Director of Key Accounts at Biomax. “The BioXM platform was developed to be a flexible knowledge management system that can be configured to any area within life sciences to provide sustainable research support. We’re pleased that Pierre Fabre sees the potential to expand this project to support multiple disciplines along their complete antibody development pipeline.”
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE